MOXATAG (Amoxicillin) 775mg tablets by MiddleBrook Pharmaceuticals Moxatag (amoxicillin extended-release) 775mg tablets will be made available by MiddleBrook Pharmaceuticals in the beginning of March ...

WESTLAKE, Texas--(BUSINESS WIRE)--MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that it has entered into an agreement with DoctorDirectory.com Inc., the Company’s promotion partner ...

Vernalis plc today announces that it has acquired the US rights to MOXATAG® (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC ("Pragma"). MOXATAG® is the first and only approved ...

MOXATAG (Amoxicillin) 775mg tablets by MiddleBrook Pharmaceuticals The FDA has approved Moxatag (amoxicillin extended-release tablets, from MiddleBrook) 775mg for the treatment of patients ≥12 years ...

MOXATAG is intended to provide a lower treatment dose, once-daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and ...

LONDON (ShareCast) - (ShareCast News) - Pharmaceutical group Vernalis (Stuttgart: BBP2.SG - news) has completed the acquisition of the US rights to the amoxicillin extended-release tablet brand ...

GERMANTOWN, Md., Jan. 24 -- MiddleBrook Pharmaceuticals, a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has received approval ...

WESTLAKE, Texas A company making a long-acting formulation of a common antibiotic has announced a program to minimize the drug’s cost to consumers. MiddleBrook Pharmaceuticals announced Wednesday a ...

WESTLAKE, Texas MiddleBrook Pharmaceuticals plans to promote its extended-release antibiotic by expanding a Web-based marketing program, the drug maker announced Wednesday. IncreaseRx is a virtual ...

Vernalis plc ("Vernalis" or the "Company") was informed yesterday that Suir Pharma Limited ("Suir") of Clonmel Ireland, the sole source supplier of finished dosage form Moxatag®, has been placed into ...